Intravitreal Bevacizumab for Diabetic Retinopathy
Author Information
Author(s): J. Fernando Arevalo, Juan G. Sanchez, Andres F. Lasave, Lihteh Wu, Mauricio Maia, Sergio Bonafonte, Miguel Brito, Arturo A. Alezzandrini, Natalia Restrepo, Maria H. Berrocal, Mario Saravia, Michel Eid Farah, Jans Fromow-Guerra, Virgilio Morales-Canton
Hypothesis
Can intravitreal bevacizumab improve outcomes in patients with diabetic retinopathy?
Conclusion
Intravitreal bevacizumab injections may improve visual acuity and reduce macular thickness in patients with diabetic retinopathy over 24 months.
Supporting Evidence
- 62 eyes remained stable after treatment.
- 72 eyes improved by two or more lines of vision.
- Mean BCVA improved significantly from baseline at all follow-up points.
Takeaway
This study shows that a medicine called bevacizumab can help people with eye problems caused by diabetes, making their vision better and their eyes healthier.
Methodology
A multicenter retrospective study of patients with diffuse diabetic macular edema treated with intravitreal injections of bevacizumab.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective and lacks a control group.
Participant Demographics
Mean age of 59.4 years, 51.3% male, with poorly controlled diabetes.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website